Friday, October 30, 2026
Via News Knowledge File

Aduro Clean Technologies Inc.

organization80% conf.·synced Aug 13, 2026

Clean technology company chemically recycling lower-value feedstocks (plastic waste, heavy bitumen, renewable oils) using proprietary Hydrochemolytic™ water-based technology operating at relatively low temperatures

50
sourced metrics
350
relationships
20
stated objectives
0
Via News reports

Every fact below is drawn from Via News's knowledge graph and linked to the source document it came from. Nothing here is unsourced. How we source →

Key metrics · each point sourced

Target Capacity
100000tons
Module Capacity
25000tons_per_module
Shares Offered Public
1028645shares
Jun 11, 2026source
Stock Price Cad
21.20CAD
Jun 11, 2026source
Gross Proceeds Life Offering
7169810USD
Jun 11, 2026source
Shares Offered Life Private Placement
471698shares
Jun 11, 2026source
Shares Offered Life Max
471698shares
Jun 11, 2026source
Offer Price Usd
15.20USD_per_share
Jun 11, 2026source
Offer Price Cad
21.20CAD_per_share
Jun 11, 2026source
Gross Proceeds Total Combined
22805214USD
Jun 11, 2026source
Total Gross Proceeds Max
22805214USD
Jun 11, 2026source
Stock Price
15.20USD
Jun 11, 2026source
Gross Proceeds Life Offering Max
7169810USD
Jun 11, 2026source
Gross Proceeds Public Offering
15635404USD
Jun 11, 2026source
Revenue Growth
73.0percent_per_annum
Apr 1, 2026source
Insider Ownership
33.9percent
Apr 1, 2026source
Earnings Growth
59percent
Apr 1, 2026source
Contract Payment
39000USD
Mar 26, 2026source

Stated objectives

Use public offering proceeds for pilot plant program, ongoing R&D, general corporate purposes, and working capital

source
target: 20 million USD stated

Complete longer-duration pilot campaigns at NGP Pilot Plant following sequential testing, wet commissioning runs, and process optimization

source
stated

Evaluate site suitability for demonstration-scale plant in Netherlands with budget of €2M plus non-refundable fees

source
target: 2 million EUR stated

Complete commissioning of NGP pilot plant and transition to long-term pilot operating campaigns

source
stated

Finalize site selection for demonstration plant

source
by 2026-01-31 00:00:00stated

Use $20M USD proceeds primarily to advance demonstration plant program, R&D investments, and general corporate purposes

source
target: 20000000 stated

Acquire land, buildings and equipment at industrial brownfield site in Netherlands for potential demonstration plant

source
target: 2000000 stated

Evaluate HCT application to real post-consumer flexible plastic packaging from Mexico through structured multi-stage Hydrochemolytic testing program from laboratory to pilot scale

source
stated

Explore business models and market pathways that could create value for ECOCE members, waste collectors and downstream commercial partners, potentially leading to HCT-based recycling solution deployment in Mexico

source
stated

Complete due diligence phase for Netherlands site

source
by 2026-01-15 00:00:00stated

Relationship graph · 350 connections

Employs
96
Developed by
68
headquartered in
36
Customer of
21
contracted by
15
located in
15
regulates
14
subsidiary of
12
This Knowledge File is assembled from Via News's source-traceable knowledge graph. Metrics, objectives and relationships are extracted from primary and credible secondary documents and refreshed on a schedule. Read our methodology →
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com